Tigermed Selects Merge eClinical to Improve Study Management Efficiency

CHICAGO, Oct. 22, 2012 -- Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that Tigermed Consulting Co., Ltd. has selected Merge eClinical's CTMS solution for Sponsors and CROs to streamline clinical trial management (CTMS) and maximize operational efficiency across its studies.

Based in Shanghai, China, Tigermed is a leading Contract Research Organization (CRO) providing regulatory, clinical and data management services. With several offices located in Asia, including China, South Korea and Japan, partnering with Merge for CTMS will support Tigermed's expansion of operations into Europe and North America.

"We were seeking a CTMS system that was cost-effective, scalable and easy to use," explained Dr. Xiaoping Ye, Chairman and General Manager at Tigermed. "With Merge CTMS, we expect to see a significant improvement in our study management efforts, allowing us to pass on cost savings to our clients."

"With Merge, our clients can be assured that we will track study enrollment and other critical study details in an easy to learn, intuitive interface, accessible via the web by our staff throughout the region," Dr. Ye continued. "This will allow us to improve study management by ensuring we have reliable, quality data."

"We are pleased to have been selected as a CTMS partner for Tigermed's global clinical trial needs," said Justin Dearborn, President of Merge Healthcare. "This is the largest single transaction Merge has entered into in China to date. With increasing demand for site and data collection solutions in the Asia-Pacific region, we believe our eClinical solution will continue to gain traction. Our straight-forward interface and simplified user experience allows studies to be managed in a fraction of the time of other solutions. Bundled with the industry's best training and support, Tigermed now has a complete study management solution in Merge CTMS."

About Merge

Merge is a leading provider of clinical systems and innovations that seek to transform healthcare. Merge's enterprise and cloud-based solutions for image intensive specialties provide access to any image, anywhere, any time. Merge also provides health stations, clinical trials software and other health data and analytics solutions that engage consumers in their personal health. With solutions that are used by providers and consumers and include more than 20 years of innovation, Merge is helping to reduce costs and improve the quality of healthcare worldwide. For more information, visit merge.com.

The Merge Healthcare logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10757

About Tigermed

Tigermed Consulting Co., Ltd. is a leading Contract Research Organization (CRO) in China dedicated to providing regulatory affairs, Phase I-IV clinical trials, data management, biostatistics, medical translation and GCP training services for healthcare products. Since its inception in 2004, Tigermed has been committed to accelerating product development timelines while reducing R&D costs and risks, helping to bring the miracles of new products to market effectively.

Cautionary Notice Regarding Forward-Looking Statements

The matters discussed in this news release may include forward-looking statements, which could involve a number of risks and uncertainties. When used in this press release, the words "will," "believes," "intends," "anticipates," "expects" and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, such forward-looking statements. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.